Oncolytic virotherapy in hematopoietic stem cell transplantation

Kazemi, Mohammad Hossein; Dehaghi, Bentolhoda Kuhestani; Roshandel, Elham; Parkhideh, Sayeh; Mehdizadeh, Mahshid; Salimi, Maryam; Hajifathali, Abbas; Hamidpour, Mohsen

doi:10.1016/j.humimm.2021.05.007

Cited by 9 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite all benefits of allo-HSCT for patients with cancer, this treatment is confined by high morbidity and mortality arising from GVHD (29,30). The expression of TIM-3 Abbreviation: GVHD, Graft-versus-host disease.…”

Section: Discussionmentioning

confidence: 99%

Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: T cell immunoglobulin and mucin domain-3 (TIM-3) is an immune-checkpoint molecule that is upregulated following allogeneic immune responses and could play an important role in the development and pathogenesis of graft-versus-host disease (GVHD). The soluble form of TIM-3 (sTIM-3) is increased following the upregulation of membranous TIM-3. Objectives: The aim of this study was to evaluate the association between plasma level of sTIM-3 and acute GVHD (aGVHD) incidence in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Blood samples were collected from 42 allo-HSCT patients and 20 healthy individuals 2 weeks after allo-HSCT. The plasma level of sTIM-3 was measured using enzyme-linked immunosorbent assay (ELISA). The clinical and demographic data of patients were collected from the clinical documents. Data analysis was evaluated using student t-test and one-way ANOVA tests. P-values less than 0.05 were assumed statistically significant. Results: Among 18 (42.8%) patients with aGVHD symptoms, 10 (23.8%) had severe GVHD and 8 (19%) experienced mild GVHD. Plasma sTIM-3 levels at day +14 were significantly higher in patients who developed aGVHD compared to allo-HSCT patients without GVHD and also the healthy control individuals (P-value = 0.015 and < 0.001). Among the aGVHD patients, the sTIM-3 levels in those with severe GVHD were approximately 2.5 times higher than those with mild GVHD (P-value < 0.001). Conclusions: We have identified a high plasma level of sTIM-3 as a valuable biomarker in predicting the development of acute GVHD, especially severe aGVHD in allo-HSCT patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Oncolytic viruses induce immunogenic cell death and indirectly increase T cells’ effectiveness through manipulating the immunosuppressive condition of the TME, releasing TAAs, inflammatory cytokines, and chemokine. In addition, oncolytic viruses directly lysis and destroy tumor cells ( 207 , 208 ). In a unique design, Haminki et al.…”

Section: Combination Of Tils With Other Anti-cancer Therapiesmentioning

confidence: 99%

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

et al. 2022

Self Cite

View full text Add to dashboard Cite

Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are recruited into the tumor site to fight against tumors. However, their small number and reduced activity limit their ability to overcome the tumor. Enhancement of TILs number and activity against tumors has been of interest for a long time. A lack of knowledge about the tumor microenvironment (TME) has limited success in primary TIL therapies. Although the advent of engineered T cells has revolutionized the immunotherapy methods of hematologic cancers, the heterogeneity of solid tumors warrants the application of TILs with a wide range of specificity. Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays, TIL therapy has regained attention as a safe personalized immunotherapy, and currently, several clinical trials are evaluating the efficacy of TIL therapy in patients who have failed conventional immunotherapies. Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast cancer has raised hope in patients with refractory solid tumors, too. Nevertheless, TIL therapy procedures face several challenges, such as high cost, timely expansion, and technical challenges in selecting and activating the cells. Herein, we reviewed the recent advances in the TIL therapy of solid tumors and discussed the challenges and perspectives.

show abstract

“…Oncolytic viruses (OVs) are wild-type or engineered viruses with anti-tumor capabilities that is able to impose direct cytotoxic or heat up the TME via upregulation of the inflammatory responses ( 206 ). Similar to chemotherapy, OVs can induce ICD, releasing neoantigens and inflammatory mediators that potentiate the immunotherapies ( 207 ).…”

Section: Combination Of Chemotherapy With Other Immunotherapiesmentioning

confidence: 99%

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

et al. 2022

View full text Add to dashboard Cite

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into molecular mechanisms and regimens that uplift the efficacy of immunotherapy since only a minority of cancer patients are responsive to immune checkpoint inhibitors (ICIs). Recent findings on combination therapy of chemotherapy and ICIs have shown promising results. This strategy increases tumor recognition and elimination by the host immune system while reducing immunosuppression by the tumor microenvironment. Currently, several preclinical studies are investigating molecular mechanisms that give rise to the immunomodulation by chemotherapeutic agents and exploit them in combination therapy with ICIs in order to achieve a synergistic clinical activity. In this review, we summarize studies that exhibit the capacity of conventional chemotherapeutics to elicit anti-tumor immune responses, thereby facilitating anti-tumor activities of the ICIs. In conclusion, combining chemotherapeutics with ICIs appears to be a promising approach for improving cancer treatment outcomes.

show abstract

Oncolytic virotherapy in hematopoietic stem cell transplantation

Cited by 9 publications

References 75 publications

Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation

Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Contact Info

Product

Resources

About